Publications
Decker M, Huang BJ, Ware T, Boone C, Tang M, Ybarra J, Ballapuram AC, Taran KA, Chen PY, Amendáriz M, Leung CJ, Harris M, Tjoa K, Hongo H, Abelson S, Rivera J, Ngo N, Herbst DM, Suciu RM, Guijas C, Sedighi K, Andalis T, Roche E, Xie B, Liu Y, Smith CC, Stieglitz E, Niphakis MJ, Cravatt BF, Shannon K. In vivo validation of the palmitoylation cycle as a therapeutic target in NRAS-mutant cancer. bioRxiv : the preprint server for biology. 2025. PMID: 40166265
Olazagasti C, Celi CV, Mahtani A, Velazquez AI, Kiel L, Sridhar A, Horiguchi M, Gonzalez M, Bernabe C, Abioye O, Dizman N, Florez N. Going Back Home: Understanding the Challenges and Discrimination of Early and Mid-Career International and Puerto Rican Medical Graduates in Oncology Fields in the United States. JCO global oncology. 2025. PMID: 40112258
Mian H, Martin TG, Pond GR, Asoori S, Popat R, Kastritis E, Martinez-Lopez J, Abdallah N, Chhabra S, Parrondo R, Ailawadhi S, Dimopoulos MA, Yong K, Durie BG, Usmani SZ, Lin Y, Tan CR. Outcomes of frailty subgroups of older adults (age ≥ 70) treated with teclistamab: an International Myeloma Foundation immunotherapy database real-world analysis. Leukemia. 2025. PMID: 40113913
Shah BD, Cassaday RD, Park JH, Houot R, Logan AC, Boissel N, Leguay T, Bishop MR, Topp MS, O'Dwyer KM, Tzachanis D, Arellano ML, Lin Y, Baer MR, Schiller GJ, Subklewe M, Abedi M, Minnema MC, Wierda WG, DeAngelo DJ, Stiff P, Jeyakumar D, Mao D, Adhikary S, Zhou L, Hadjivassileva T, Damico Khalid R, Ghobadi A, Oluwole OO. Three-year analysis of adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3. Leukemia. 2025. PMID: 40108332
Shah BD, Cassaday RD, Park JH, Houot R, Logan AC, Boissel N, Leguay T, Bishop MR, Topp MS, O'Dwyer KM, Tzachanis D, Arellano ML, Lin Y, Baer MR, Schiller GJ, Subklewe M, Abedi M, Minnema MC, Wierda WG, DeAngelo DJ, Stiff P, Jeyakumar D, Mao D, Adhikary S, Zhou L, Hadjivassileva T, Damico Khalid R, Ghobadi A, Oluwole OO. Three-year analysis of adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3. Leukemia. 2025. PMID: 40108332
Athanas R, Frumence G, DeBoer RJ, Ulrich CM. Is It a Bribe? Research Personnels' Perceptions of the Ethical Aspects of Financial Compensation to Healthy Volunteers in Prevention Trials in Tanzania. AJOB empirical bioethics. 2025. PMID: 40105119
Park YH, Bianchini G, Cortés J, Licata L, Vidal M, Iihara H, Roeland EJ, Jordan K, Scotté F, Schwartzberg L, Navari RM, Aapro M, Rugo HS. Nausea and vomiting in an evolving anticancer treatment landscape: long-delayed and emetogenic antibody-drug conjugates. Future oncology (London, England). 2025. PMID: 40105595
Xu MJ, Okerosi S, Nkya A, Van Loon K. Strategically striving to be more inclusive: A recommendation for gender-neutral human-papillomavirus vaccine policies. Human vaccines & immunotherapeutics. 2025. PMID: 40098479
Sorror ML, Saber W, Logan BR, Geller NL, Bellach A, Kou J, Wood WA, McCarty J, Knight TG, Runaas L, Johnston LJ, Walston JD, Nakamura R, Jarrett L, Mishra A, Uberti J, Dahi PB, Saultz JN, McCurdy SR, Morris LE, Imus P, Hogan WJ, Nadiminti KVG, Bhatt VR, Olin RL, Maakaron J, Sobecks RM, Wall SA, Mattila D, Protz B, Devine SM, Horowitz MM, Artz AS. Novel Composite Health Assessment Risk Model for Older Allogeneic Transplant Recipients: BMT-CTN 1704. Blood advances. 2025. PMID: 40101246
Moussavi-Baygi R, Ryan MJ, Sim W, Hoelscher SB, Luga V, Chandrakumar AA, Hoes L, Cha J, Lee YS, Herm K, Doron B, Ding CKC, Stohr BA, Jin P, Nadkarni T, Fang X, Haryono M, Nguyen A, Karthaus WR, Sawyers C, Feng FY, Goodarzi H, Bose R. Stochastically Emergent Tumors offer in vivo whole genome interrogation of cancer evolution from non-malignant precursors. bioRxiv : the preprint server for biology. 2025. PMID: 40166351
Janni W, Friedl TWP, Yab TC, Bidard FC, Cristofanilli M, Hayes DF, Ignatiadis M, Regan MM, Alix-Panabieres C, Barlow WE, Caldas C, Carey LA, Dirix L, Fehm T, Garcia-Saenz JA, Gazzaniga P, Generali D, Gerratana L, Gisbert-Criado R, Jacot W, Jiang Z, Joosse SA, Lianidou E, López López R, Magbanua MJM, Manso L, Mavroudis D, Müller V, Munzone E, Pantel K, Pierga JY, Rack B, Riethdorf S, Rugo HS, Sideras K, Sleijfer S, Smerage J, Stebbing J, Terstappen LWMM, Vidal-Martínez J, Wallwiener M, Giridhar KV, Liu MC. Clinical validity of repeated circulating tumor cell enumeration as an early treatment monitoring tool for metastatic breast cancer in the PREDICT global pooled analysis. Clinical cancer research : an official journal of the American Association for Cancer Research. 2025. PMID: 40100138
Harbeck N, Dieras V, Gelmon KA, Finn RS, Martin M, Neven P, Kim S, Ma J, Gauthier E, Broughton E, Doan J, Rugo HS. Effect of palbociclib plus letrozole on patient-reported health-related quality of life: extended follow-up of the PALOMA-2 trial. ESMO open. 2025. PMID: 40107156
Rugo HS, Bardia A, Schmid P, Tolaney SM, Dasgupta A, Kaushik A, Verret W, Gosset M, Brufsky A, Cortés J, Marmé F. Q-TWiST Analysis of Sacituzumab Govitecan vs. Chemotherapy in Previously Treated Patients with HR+/HER2- Metastatic Breast Cancer. Current oncology (Toronto, Ont.). 2025. PMID: 40136373
Gluz O, Xu B, Nanda R, Dasgupta A, Kaushik A, Verret W, Sharma A, Singh B, Rugo HS. Efficacy of sacituzumab govitecan versus treatment of physician's choice in previously treated HR+ and HER2- mBC: a meta-analysis of TROPiCS-02 and EVER-132-002 trials. Therapeutic advances in medical oncology. 2025. PMID: 40093981
Chari A, Touzeau C, Schinke C, Minnema MC, Berdeja JG, Oriol A, van de Donk NWCJ, Rodríguez-Otero P, Morillo D, Martinez-Chamorro C, Mateos MV, Costa LJ, Caers J, Rasche L, Krishnan A, Ye JC, Karlin L, Lipe B, Vishwamitra D, Skerget S, Verona R, Ma X, Qin X, Ludlage H, Campagna M, Masterson T, Hilder B, Tolbert J, Renaud T, Goldberg JD, Kane C, Heuck C, San-Miguel J, Moreau P. Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1-2 study. The Lancet. Haematology. 2025. PMID: 40090350
Caston NE, Deng L, Williams CP, Levitan EB, Azuero A, Griffin R, Smith KL, Wolff AC, Melisko ME, Shinn EH, Gallagher K, Angove R, Wheeler SB, Rocque GB. System-Level Transformations to Increase Patient Participation in Clinical Trials. JCO oncology practice. 2025. PMID: 40080789
Chari A, Bal S, Ailawadhi S, Krishnan A, Patel KK, Berdeja JG, Garfall A, Callander N, Banerjee R, Alsina M, Nooka AK, Dhakal B, Gasparetto C, Costello C. Expert Perspectives on Current Challenges and Emerging Approaches for Multiple Myeloma: Narrative Review of an Inaugural Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma. Clinical lymphoma, myeloma & leukemia. 2025. PMID: 40175263
Meric-Bernstam F, Bardia A, Bossi P, Bianchini G, Gatlin F, Lalla RV, Melosky B, Niikura N, Yap TA, Kim SS, Rajagopalan R, Fairhurst RM, Graff SL, Rugo HS. Prophylaxis, clinical management, and monitoring of datopotamab deruxtecan-associated oral mucositis/stomatitis. The oncologist. 2025. PMID: 40139260
Lizeth Estrada, Farhana Moon, Le Bryan Khuong, Li Zhang, Alan Paciorek, Paige Steiding, Claire Mulvey, Emily Bergsland. Characterization of early-onset gastroenteropancreatic neuroendocrine neoplasms at UCSF. Endocrine Abstracts. 2025. PMID:
Alan Paciorek, Lizeth Estrada, Farhana Moon, Le Bryan Khuong, Li Zhang, Paige Steiding, Claire Mulvey, Emily Bergsland. Disparities in the rising incidence of early-onset neuroendocrine neoplasms. Endocrine Abstracts. 2025. PMID: